

Notice of Allowability	Application No.	Applicant(s)	
	10/772,281	SAWAI ET AL.	
	Examiner	Art Unit	
	B. Dell Chism	1654	

-- *The MAILING DATE of this communication appears on the cover sheet with the correspondence address--*

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to papers filed 10 March 2006.
2. The allowed claim(s) is/are 1-12 and 15-25.
3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some* c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No./Mail Date _____.
 - (b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. Notice of References Cited (PTO-892)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)
3. Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____
4. Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. Notice of Informal Patent Application (PTO-152)
6. Interview Summary (PTO-413),
Paper No./Mail Date _____.
7. Examiner's Amendment/Comment
8. Examiner's Statement of Reasons for Allowance
9. Other _____.

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Thomas Cunningham on 11 May 2006.

Please amend the application as follows:

In the Preliminary Amendment to the Specification filed on 06 February 2004, delete the first two sentences and replace with the following: --This application is a divisional of U.S. Serial No. 09/786,125, filed March 1, 2001, now U.S. Patent No. 6,774,104, which is the national-stage under 35 U.S.C. §371 of PCT/JP00/04381, filed 06/29/00. This application also claims priority to JAPAN 11/187713, filed July 1, 1999.--

Please amend the claims as follows:

Claim 1, line 4, delete "group, or" and insert --group; or--.

Claim 1, line 5, delete ", and" and insert --; and--.

Claim 3, line 2, insert --is—between "compound" and "a disaccharide".

Claim 15, line 3, delete "matter associated therewith, wherein the written matter states that the pharmaceutical composition can or should be used for preventing or treating infections or disease" and insert --instructions for use thereof--.

Claim 25, line 2, delete "wherein said disease is selected from the group consisting of".

2. The following is an examiner's statement of reasons for allowance: the instantly claimed invention is drawn to a stabilized pharmaceutical composition in lyophilized form comprising a *cyclic polypeptide compound of general formula (I)*... and *one or more compound(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride*. The Examiner notes for the record that when the claims refer to "said compound" the reference is to the group consisting of a polysaccharide, disaccharide or sodium chloride; and when the claims refer to "cyclic polypeptide compound" the reference is to the compound of general formula (I). The independent and dependent claims use the terminology consistently and without ambiguity.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

3. Claims 1-12 and 15-25 are allowed.


4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism, whose telephone number is (571) 272-0962. The examiner can normally be reached on M-F 08:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell, PhD can be reached on (571) 272-0974.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for

Art Unit: 1654

published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

BDC



B. DELL CHISM
PATENT EXAMINER